Novartis’ Lutathera, a drug indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, including foregut, midgut, and hindgut tumors, was recently highlighted at the World Congress on Gastrointestinal Cancer 2021. Dr. Jonathan R. Strosberg, head of the Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in…